Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
-
Rahm reaches separation deal with LIV in bankruptcy court
-
ATP proposes rankings system changes, extra player bonuses
-
UN chief urges nations to end 'war on nature'
-
Russell Brand was 'monster-like', alleged victim tells UK court
-
Newcastle boss Jaissle says Fernandez-Pardo just needs a goal
-
Crowded Launches Crowded MCP, Bringing Nonprofit Financial Operations Into ChatGPT and Claude
-
Infantino offers apology but 'no answers' at FIFA meeting over World Cup plan
-
Albanian PM condemns 'chaos' as violent unrest spreads
-
Don't exclude Turkey from 'Made in Europe' plan: minister to AFP
-
Italian football suffers new blow with Champions League misery
-
French duo Justice to score 'GTA VI': game maker
-
Trump scraps plan to livestream execution after broad backlash
-
El Nino a 'terrifying' threat to coral reefs: UN biodiversity expert
-
Seven missing off Romania after latest Black Sea drone attacks
-
Barcola must get used to Liverpool highs and lows, says Iraola
-
ARKBRIDGE Outlines Jonathan Morelli’s “Picks and Shovels” AI Infrastructure Investment Strategy
-
Versus Trade Wins Best ECN/STP Broker APAC 2026, Marking Third UF Awards Recognition
-
Tech sell-off rolls on as hot inflation data stokes rate worries
-
Three dead as Istanbul sees heaviest rainfall in 80 years
-
McIlroy makes 'solid' start in rain-hit Delhi as Norgaard leads
-
US producer prices see biggest jump since 2022 in added challenge to Trump
-
Seven missing after fire on vessel in Black Sea off Romania
-
Swiatek avoids seed exodus to breeze into Wuhan last eight
-
'Severe drought' declared in parts of UK
-
PM condemns 'chaos' as violent protests grip Albania
-
IUX Announces New Web Client Portal Built for Enhanced Browser-Based Trading
-
'I couldn't breathe', Russell Brand's alleged rape victim says
-
School roof collapse kills teacher, 32 children in NW Pakistan
-
Pope's cancer operation already reshaping papacy
-
Inter skipper Martinez facing month out with thigh injury
-
Zverev cruises past De Minaur to reach Shanghai semi-finals
-
Spanish prosecutors back abuse probe into Julio Iglesias
-
Ukraine's Zelensky defies Trump with Russian refinery strikes
-
Tech sell-off deepens as US inflation sparks AI jitters
-
Holders Australia edge New Zealand 24-22 to open Rugby league World Cup
-
Southgate does not forsee a return to management
-
'Ocarina of Time': Nintendo gives Zelda classic a modern makeover
-
Two dead as Istanbul endures heaviest rainfall in 80 years
-
France charges teen shooter citing revenge for bullying in school
-
After latest Nepal flood, survivors fear for future
-
Martinez blames 'anger' for dig at Man Utd hierarchy
-
EU leaders clash over budget as spectre of French elections looms
-
Crowds build as Albanian PM tours protest aftermath
-
'No place to breathe': life in Indonesia's fire epicentre
-
China-North Korea bridge opens, 12 years late
-
'Can't sleep': Spain's housing crunch upends lives
-
Asian Cup in Saudi Arabia could be postponed but 'no hurry' to decide: AFC
-
Musk calls on Ukraine's Zelensky to 'go' after satellite slowdown row
-
Conrad wields axe after South Africa loss to Australia
-
Still smiling at 117, Albanian may be world's oldest woman
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.
Details for the presentation are as follows:
Abstract Number: 123
Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma
Presenter: Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute
Date & Time: Wednesday, March 12, 2025 at 5:10 p.m. - 6:45p.m. PT
For more information, please visit the conference website here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
S.Jackson--AT
